Volume 184 - Issue 1
The aromatase inhibitors in early breast cancer: who, when and why?
Author: Glen Pater
Med J Aust 2006; 184 (1): 46-47. || doi: 10.5694/j.1326-5377.2006.tb00106.x
Published online: 2 January 2006
Published online: 2 January 2006
Glen Pater
Director, Medical and Regulatory Affairs, AstraZeneca Australia, PO Box 131, North Ryde, NSW 1670. Glen.PaterATASTRAZENECA.COM
In reply: In response to Rodger, AstraZeneca would like to reiterate that the company had no role in the content of the article published by Nordman and colleagues in the 4 July issue of The Medical Journal of Australia.1
AstraZeneca has provided Sydney Cancer Centre with an unrestricted educational grant. Along with Rodger, we commend the authors on their transparency about how this grant was applied.
References
- Nordman IC, Spillane AJ, Hamilton AL. The aromatase inhibitors in early breast cancer: who, when and why? Med J Aust 2005; 183: 24-27.<eMJA full text>